Latest Breaking News On - Luke mid america heart institute mikhail kosiborod - Page 1 : comparemela.com

Semaglutide 2.4 mg Shows Benefit as Treatment for Heart Failure with Obesity

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.